WESTMINSTER, Colo., June 23, 2025 /PRNewswire/ — Cerapedics Inc., a global, commercial-stage orthopedics company dedicated to redefining the path to bone repair, today announced the U.S. Food and Drug Administration (FDA) premarket approval (PMA) of PearlMatrix™ P-15 Peptide Enhanced Bone Graft as a Class III drug-device combination product for use in single-level transforaminal lumbar interbody fusion (TLIF) surgery in adult patients with degenerative disc disease (DDD). Despite the availability of over 350+ spinal bone grafts, none have demonstrated a substantial improvement in fusion speed until now. Powered by a proprietary P-15 Osteogenic Cell Binding Peptide, PearlMatrix Bone Graft is the first and only bone growth accelerator (BGA) proven to accelerate lumbar fusion.

New imaging innovation enhances wound assessment by combining fluorescence and thermal data for improved diagnostic precision and patient care

Meril Life Sciences, a leading global med-tech company, marked a significant milestone with the launch of MyClip, India’s first Transcatheter Edge-To-Edge Repair (TEER) system, on June 14

Brain-computer interface (BCI) developer Science Corporation today said it submitted its Prima retinal implant for CE mark approval.